Beeline Medicines Initiates Phase 2/3 Lupus Trial
Beeline Medicines says it has initiated its first trial in its lupus pivotal development program: a global Phase 2/3 study of afimetoran in cutaneous lupus erythematosus.
Related stories
Twin Disc Maintains Quarterly Dividend at $0.05 per Share
Twin Disc kept its quarterly dividend at $0.05 per share, payable Dec. 1 to holders of record Nov. 18.
M impact | EQUITY | Nov 02, 2026, 02:42 PM UTC
Ryanair CEO Sees European Airfares Rising Up to 20% Next Year
Ryanair’s CEO expects European plane ticket prices may climb as much as 20% next year, with jet fuel prices rising.
L impact | EQUITY | Nov 02, 2026, 02:42 PM UTC
Sigma Lithium Plans $100M Convertible Bond Due 2031
Sigma Lithium said proceeds are intended to repay its Synergy Capital secured debt in full, with the balance for growth capital expenditure and general corporate purposes.
M impact | EQUITY | Nov 02, 2026, 02:42 PM UTC
Sigma Lithium to Refinance Senior Debt and Extend Maturities to 2031
Sigma Lithium says net proceeds will refinance its senior secured debt in full with Synergy Capital and extend its debt maturity profile to 2031.
L impact | EQUITY | Nov 02, 2026, 02:41 PM UTC
IDBI Bank Employees Begin Two-Day Strike Over Planned Privatisation
IDBI Bank employees began a two-day nationwide strike Monday against the planned privatisation and proposed sale to Fairfax Financial Holdings. More than 10,000 staff across over 2
L impact | EQUITY | Nov 02, 2026, 02:41 PM UTC
Tempus AI shares rise 6.2% after Q3 profit
M impact | EQUITY | Nov 02, 2026, 02:40 PM UTC